Biocept issues letter to stockholders

San diego--(business wire)--biocept, inc. (nasdaq: bioc), a leading commercial provider of molecular testing to provide physicians with clinically actionable information to improve patient outcomes, announces that president and ceo michael w. nall has issued the following letter to stockholders: to my fellow stockholders: biocept entered 2021 well-positioned to grow our core liquid biopsy oncology business while continuing to offer rt-pcr testing for the sars-cov-2 virus. oncology testing is ou
BIOC Ratings Summary
BIOC Quant Ranking